Changes in the Management Team of Biohit Oyj

BIOHIT OYJ STOCK EXCHANGE RELEASE ON 22 June 2011 AT 2:00 PM


Nina Hasu, MSc (Econ.), born 1970, has been appointed Financial Director and member of the Management Team of Biohit Oyj as of 8th August, 2011, replacing Tiina Hankonen. Hasu has previously worked as Business Controller at UPM-Kymmene Wood Oy.

***

Elina Ämmälä, M.Pol.Sc, born 1976, has been appointed Communications Director of Biohit Oyj as of 8th August, 2011, replacing Josefin Hoviniemi. Prior to entering the services of Biohit, Ämmälä worked as Director at Cocomms Oy, a communications consulting company.


Further information:

Jussi Heiniö
CEO, Biohit Oyj
Tel. +358 9 773 861, mobile +358 400 701180
jussi.heinio@biohit.com

Biohit in brief:

Biohit is a globally operating Finnish biotechnology company that was established in 1988. The company’s mission is to improve human health and quality of life. The company follows a goal-directed and long-term innovation and patenting strategy.

Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective liquid handling solutions for laboratory work as well as diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. The end users of Biohit’s products are e.g. the pharmaceutical industry, the food industry, research institutes and universities as well as the public and private healthcare sectors.

Biohit has two business segments: Liquid Handling and Diagnostics. Liquid Handling products include electronic and mechanical pipettes, disposable tips as well as pipette maintenance and calibration services. The Diagnostics business comprises products and analysis systems for the early diagnosis and prevention of gastrointestinal diseases, such as the blood-sample based GastroPanel examination for the diagnosis of stomach illnesses and associated risks, and Acetium capsules, which bind carcinogenic acetaldehyde in the stomach.

In 2010, Biohit’s net sales were MEUR 40 and the company employed approximately 400 people. Biohit is headquartered in Helsinki, Finland, and has production facilities in Helsinki, Kajaani and in Suzhou, China. It has subsidiaries in France, Germany, the UK, Russia, India, China, Japan and the USA. The company also has a representative office in Singapore. Biohit's products are also sold through about 200 distributors in 70 countries.

Biohit's Series B share is quoted on NASDAQ OMX Helsinki in the Small Cap/Healthcare group and is traded under the code BIOBV.

More information: www.biohit.com.